Just ahead of the FDA Advisory Committee hearing on rivaroxaban for stroke prevention in atrial fibrillation, we report in more depth on the ROCKET-AF trial results published recently in the New England Journal of Medicine. Rivaroxaban was shown to be as effective as warfarin (Coumadin) for stroke prevention in a high-risk afib population. To learn [...]
Dr. Elaine Hylek on Xarelto and Pradaxa, New Alternatives to Warfarin (Coumadin) — Video
The US FDA has just announced that on September 8, 2011, the FDA Cardiovascular and Renal Drugs Advisory Committee will meet to review whether to recommend approval of rivaroxaban (brand name Xarelto), an alternative to warfarin, for stroke prevention in atrial fibrillation. In this recent video interview, Dr. Elaine Hylek, a leading anticoagulant authority, discussed [...]
2010 Most Popular Atrial Fibrillation News Stories and Videos
StopAfib.org has published the 2010 Most Popular Atrial Fibrillation News Stories and Videos List. Stroke prevention topped the list and included stories about warfarin (Coumadin) and alternatives such as dabigatran (Pradaxa) and rivaroxaban (Xarelto). Other popular topics included the new European atrial fibrillation guidelines, new antiarrhythmic medications, updates on catheter ablation and afib surgery, and [...]
Breaking News: Rivaroxaban As Good as Warfarin for Atrial Fibrillation Stroke Prevention
In late breaking clinical trials presented today at the American Heart Association Scientific Sessions, results of the ROCKET AF trial indicated that in an atrial fibrillation patient population that was at a very high risk of stroke, rivaroxaban (Xarelto) was as good as warfarin at preventing strokes. Learn more at: Rivaroxaban comparable to warfarin in [...]
Breaking News: FDA Panel Unanimously Recommends Approval of Dabigatran to Decrease Stroke Risk in Atrial Fibrillation
An FDA panel today unanimously recommended that the FDA approve dabigatran (Pradaxa) for reducing the risk of afib strokes. FDA approval is expected quickly, making this the first alternative to warfarin approved in the United States, and also the first atrial fibrillation approval for dabigatran. It is approved in over 70 countries for venous thromboembolisms [...]
@stopafib to live-tweet from FDA hearing on Dabigatran to replace warfarin for afib
Next Monday, September 20, 2010, StopAfib.org will be covering the FDA’s hearing on dabigatran (Pradaxa), the new alternative to warfarin, and will be “live-tweeting” from the hearing. Get first reports as they happen by following @stopafib on Twitter. If you’re already on Twitter, just follow us from the toolbar at the bottom of this page. [...]
Mexican Americans with Atrial Fibrillation (AF) Have More and Worse Strokes
A new study exploring ethnic differences in stroke risk for people with atrial fibrillation (AF) showed that Mexican American stroke survivors with afib were more than twice as likely to have another stroke as comparable non-Hispanic white stroke survivors with afib. Researchers were surprised by the study’s finding that severity of recurrent stroke is also [...]
Learn About Atrial Fibrillation (Afib) with a New Guide
Whether you’re an atrial fibrillation patient or caregiver, or are just interested in learning more about afib, check out the new Get Started Learning About Atrial Fibrillation Guide at StopAfib.org. You’ll find a wealth of information, including: what afib is and the problems it causes, including stroke and congestive heart failure information about an afib [...]
Dr. Peter Kowy: Atrial Fibrillation Drugs & Trials [StopAfib.org interview]
StopAfib.org interviews Dr. Peter Kowey See the full transcript at: www.stopafib.org In this video interview at Boston Atrial Fibrillation Symposium 2010, Dr. Peter Kowey talked about a number of exciting new things in the atrial fibrillation world, including the Cabana clinical trials, the Safari catheter ablation registry, dronedarone as a
